Protalix BioTherapeutics, Inc. (DE) (PLX): Price and Financial Metrics

Protalix BioTherapeutics, Inc. (DE) (PLX): $1.06

-0.04 (-3.64%)

POWR Rating

Component Grades













Add PLX to Watchlist
Sign Up

Industry: Biotech



in industry


  • PLX scores best on the Value dimension, with a Value rank ahead of 81.83% of US stocks.
  • PLX's strongest trending metric is Sentiment; it's been moving up over the last 161 days.
  • PLX ranks lowest in Momentum; there it ranks in the 9th percentile.

PLX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PLX is 231.44 -- better than 99.83% of US stocks.
  • With a one year PEG ratio of 0.35, Protalix BioTherapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 2.41% of US stocks.
  • PLX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 0.5% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Protalix BioTherapeutics Inc, a group of peers worth examining would be PTCT, POLY, STX, PRO, and AGEN.
  • Visit PLX's SEC page to see the company's official filings. To visit the company's web site, go to

PLX Valuation Summary

  • In comparison to the median Healthcare stock, PLX's price/sales ratio is 85.9% lower, now standing at 1.6.
  • Over the past 243 months, PLX's price/sales ratio has gone NA NA.
  • Over the past 243 months, PLX's EV/EBIT ratio has gone down 7.8.

Below are key valuation metrics over time for PLX.

Stock Date P/S P/B P/E EV/EBIT
PLX 2021-08-31 1.6 19.4 -3.6 -8.2
PLX 2021-08-30 1.5 18.6 -3.4 -7.9
PLX 2021-08-27 1.5 19.0 -3.5 -8.0
PLX 2021-08-26 1.5 18.1 -3.4 -7.8
PLX 2021-08-25 1.4 17.5 -3.2 -7.6
PLX 2021-08-24 1.3 16.4 -3.0 -7.3

PLX Growth Metrics

    The 5 year price growth rate now stands at -57.47%.
  • Its year over year cash and equivalents growth rate is now at 39.98%.
  • Its 5 year net cashflow from operations growth rate is now at 30.15%.
PLX's revenue has moved up $15,056,000 over the prior 33 months.

The table below shows PLX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 49.296 -12.748 -20.518
2021-06-30 48.032 -14.472 -20.756
2021-03-31 52.572 -28.823 -13.665
2020-12-31 62.898 -26.106 -6.523
2020-09-30 61.162 -22.243 -6.629
2020-06-30 64.62 -21.864 -5.752

PLX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PLX has a Quality Grade of C, ranking ahead of 73.31% of graded US stocks.
  • PLX's asset turnover comes in at 0.547 -- ranking 71st of 681 Pharmaceutical Products stocks.
  • MNKD, XTNT, and NBIX are the stocks whose asset turnover ratios are most correlated with PLX.

The table below shows PLX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.547 0.685 -0.240
2021-03-31 0.668 0.768 -0.088
2020-12-31 0.853 0.827 0.039
2020-09-30 0.898 0.819 0.028
2020-06-30 1.019 0.823 0.046
2020-03-31 1.111 0.814 -0.008

PLX Stock Price Chart Interactive Chart >

Price chart for PLX

PLX Price/Volume Stats

Current price $1.06 52-week high $3.08
Prev. close $1.10 52-week low $0.70
Day low $1.06 Volume 251,500
Day high $1.11 Avg. volume 2,539,411
50-day MA $1.16 Dividend yield N/A
200-day MA $1.11 Market Cap 49.89M

Protalix BioTherapeutics, Inc. (DE) (PLX) Company Bio

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company was founded in 1993 and is based in Carmiel, Israel.

PLX Latest News Stream

Event/Time News Detail
Loading, please wait...

PLX Latest Social Stream

Loading social stream, please wait...

View Full PLX Social Stream

Latest PLX News From Around the Web

Below are the latest news stories about Protalix BioTherapeutics Inc that investors may wish to consider to help them evaluate PLX as an investment opportunity.

Protalix, Chiesi Global file for EU approval of PRX-102 for Fabry disease

Protalix BioTherapeutics (NYSE:PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., submitted an application via centralized procedure to the European Medicines Agency (EMA) for pegunigalsidase alfa (PRX–102) to treat adults with Fabry disease. The Marketing Authorization Application (MAA) is backed by preclinical, clinical and manufacturing data from completed and...

Seeking Alpha | February 24, 2022

Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that there will be two poster presentations regarding the Company's pegunigalsidase alfa or PRX–102 candidate under development for the treatment of Fabry disease at the 18th Annual WORLDSymposium™ 2022, taking

Yahoo | February 3, 2022

Protalix Biotherapeutics: Is It Worth The Wait?

No summary available.

Seeking Alpha | January 7, 2022

Protalix BioTherapeutics Issues 2021 Letter to Stockholders

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.

Yahoo | December 22, 2021

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) Shares Bought by Morgan Stanley

Morgan Stanley raised its stake in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) by 3,723,538.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,861,819 shares of the companys stock after acquiring an additional 1,861,769 shares during the period. Morgan Stanleys holdings in Protalix BioTherapeutics []

Dakota Financial News | December 12, 2021

Read More 'PLX' Stories Here

PLX Price Returns

1-mo -8.62%
3-mo 29.24%
6-mo 7.07%
1-year -61.17%
3-year -72.61%
5-year -88.48%
YTD 27.45%
2021 -77.09%
2020 10.67%
2019 5.47%
2018 -52.95%
2017 50.23%

Continue Researching PLX

Want to see what other sources are saying about Protalix BioTherapeutics Inc's financials and stock price? Try the links below:

Protalix BioTherapeutics Inc (PLX) Stock Price | Nasdaq
Protalix BioTherapeutics Inc (PLX) Stock Quote, History and News - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7726 seconds.